From my understanding in profits and sp for Neu it is a good time to enter and hold. Best part is corporate expenses are not very high as compared to other biotechs. $65 million is the project royality next year and on a pe of 20 that will make eligible for $11 But that does not include canada, europe, japan and once it went to those countries royalities can be doubled in 3 year, which make it eligible for $22 per share. on top we are going to get milestone payments. That is in respect to the fact that all other three phase 3 products are not approv d by FDA and all the expenses are borne by NEU. If another product get FDA green light then NEU can be easily into $30 club, but if all the all three products get approval from FDA that can see us in beyond $50. So to me it is almost derisked sp for anyone to buy and hold neu for 2 years plus. dyor
NEU Price at posting:
$13.21 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)